Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 125-131

  Ahn, Mee Young ^a   Chung, Hae Young ^a   Choi, Wahn Soo ^b   Lee, Byung Mu ^c   Yoon, Sungpil ^d   Kim, Hyung Sik ^a  

^a Pusan National University   (South Korea)

^b Konkuk University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d National Cancer Center   (South Korea)

Author keywords

Apicidin; Apoptosis; Endometrial cancer; Histone deacetylase inhibitor; Xenograft model

Indexed keywords

APICIDIN; CYCLINE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE H3; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL; CANCER INHIBITION; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM CANCER; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDES, CYCLIC; REPRESSOR PROTEINS;

EID: 74549147514     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000483     Document Type: Article

References (40)

1. Dokmanovic M, Clarke C and Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989, 2007.
2. Glozak MA and Seto E: Histone deaceylase and cancer. Oncogene 26: 5420-5432, 2007.
3. Choi JH, Kwon HJ, Yoon BI, et al: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92: 1300-1304, 2001.
4. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE and Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189, 2004.
5. Kawai H, Li H, Avraham S, Jiang S and Avraham HK: Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α. Int J Cancer 107: 353-358, 2003.
6. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP and Gottlicher M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463, 2004.
7. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002.
8. Monneret C: Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs 18: 363-370, 2007.
9. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone-deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
10. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006.
11. Carew JS, Giles FJ and Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269: 7-17, 2008.
12. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK and Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528, 2005.
13. Lindemann RK and Johnstone RW: Histone deacetylase inhibitors: promising candidates for chemotherapeutic drugs. Gene Ther Mol Biol 8: 61-74, 2004.
14. Mei S, Ho AD and Mahlknecht U: Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int J Oncol 25: 1509-1519, 2004.
15. Acharya MR, Sparreboom A, Venitz J and Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68: 917-932, 2005.
16. Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, Cannova C, Meinke PT, Colletti SL, Bednarek MA, Singh SB, Goetz MA, Dombrowski AW, Polishook JD and Schmatz DM: Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA 93: 13143-13147, 1996.
17. Andrews KT, Walduck A, Kelso MJ, Fairlie DP, Saul A and Parsons PG: Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Int J Parasitol 30: 761-768, 2000.
18. Ahn MY, Lee JW, Na YJ, Choi WS, Lee BM, Kang KW and Kim HS: Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact 179: 169-177, 2009.
19. Ahn MY, Na YJ, Lee JW, Lee BM and Kim HS: Apicidin induces apoptosis via Cytochrome c-mediated intrinsic pathway in human ovarian cancer cells. Biomole & Therape 17: 17-24, 2009.
20. Amant F, Moerman P, Neven P, Timmerman D, van Limbergen E and Vergote I: Endometrial cancer. Lancet 366: 491-505, 2005.
21. Delmonte A and Sessa C: Molecule-targeted agents in endometrial cancer. Curr Opin Oncol 20: 554-559, 2008.
22. Takai N and Narahara H: Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 14: 2548-2553, 2007.
23. Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG and Köbel M: Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10: 1021-1027, 2008.
24. Jiang S, Dowdy SC, Meng XW, Wang Z, Jones MB, Podratz KC and Jiang SW: Histone deacetylase inhibitors induce apoptosis in both type I and type II endometrial cancer cells. Gynecol Oncol 105: 493-500, 2007.
25. Noh JH, Song JH, Eun JW, Kim JK, Jung KH, Bae HJ, Xie HJ, Ryu JC, Ahn YM, Wee SJ, Park WS, Lee JY and Nam SW: Systemic cell-cycle suppression by Apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells. Int J Mol Med 24: 205-226, 2009.
26. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
27. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW and Kim KW: Histones deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001.
28. Kazi AA and Koos RD: Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway. Endocrinology 148: 2363-2374, 2007.
29. Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, Krissansen GW and Sun X: Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 99: 2055-2061, 2008.
30. Garber K: HDAC inhibitors overcome first hurdle. Nat Biotechnol 25: 17-19, 2007.
31. Paris M, Porcelloni M, Binaschi M and Fattori D: Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51: 1505-1529, 2008.
32. Witt O, Deubzer HE, Milde T and Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21, 2009.
33. Marks PA and Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107: 600-608, 2009.
34. Weichert W, Roske A, Gekeler V, Beckers T, Ebert EP, Pross M, Dietel M, Denkert C and Rocken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148, 2008.
35. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M and Kristiansen G: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98: 604-610, 2008.
36. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T and Denkert C: Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14: 1669-1677, 2008.
37. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH and Mariadason JM: Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548-13558, 2006.
38. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, Feng J, Liu D and Chiao JW: De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 33: 375-380, 2008.
39. Chauchereau A, Mathieu M, de Saintignon J, Ferreira R, Pritchard LL, Mishal Z, Dejean A and Harel-Bellan A: HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia associated protein PLZF. Oncogene 23: 8777-8784, 2004.
40. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, Mariadason JM: HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 19: 4062-4075, 2008.